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ABSTRACT 
Objectives: A supplemental test was evaluated for hepatitis C 
virus (HCV). 
Methods: One hundred forty-six sera that were inconclusive or 
discrepant in two screening tests for HCV infection were eval- 
uated using a supplemental test, MATRIX-HCV2TM (Abbott Lab- 
oratories, Chicago, IL, USA). Results of the supplemental test 
were compared to the detection of HCV RNA by a nested poly- 
merase chain reaction after a step of reverse transcription (RT- 
PCR). 
Results: Thirty-nine RNA-containing sera (positive with RT-PCR) 
of 40 (97%) reacted with at least one antigen in the supple- 
mental test. Reactivity with one to three antigens also was 
observed with 77 PCR-negative sera (66%). Twenty-nine sera 
were found negative with both techniques. 
Conc/usions: Despite clear results and good sensitivity, the 
MATRIX-HCV2TM assay was poorly predictive of viremia in 
patients with indeterminate results in initial screening assays. 
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Since the introduction of the first serologic assay for 
hepatitis C virus (HCV), the sensitivity and specificity of 
tests have been improved by combining several peptides 
from the core and the nonstructural regions of the viral 
genome.’ Third-generation assays use novel antigens by 
adding a peptide coded by the NS5 region.’ Supplemen- 
tal assays were introduced for confirmation of serology 
results. They are considered to be less sensitive but more 
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specific, because they test reactivity to specific recom- 
binant antigens.3 Two tests have been developed by 
Abbott Laboratories (Chicago, IL, USA). The first uses two 
plastic beads coated respectively with structural and 
nonstructural recombinant peptides (HCV-EIATM Sup- 
plemental assay).* The second, an immunodot, semi- 
quantitative assay tests separately reactivity to peptides 
corresponding to core NS3 and NS4 regions of the HCV 
genome (MATRIX-HCV2TM).5 
To better evaluate these supplemental tests for the 
diagnosis of HCV infections, the authors studied 146 sera 
that gave different or inconclusive results with two 
screening tests. The MATRIX-HCV2TM was run in parallel. 
Results of serology were compared to the detection of 
viral RNA in sera by polymerase chain reaction after 
reverse transcription (RT-PCR). 
SUBJECTS AND METHODS 
Patient Sera 
From September 1993 to November 1994, 10,399 sero- 
logic tests for hepatitis C virus were performed in the 
laboratory; 146 of them (1.4%) gave different or incon- 
clusive results with two screening tests. The patients were 
mainly from the wards of infectious diseases in charge of 
human immunodeficiency virus (HIV)-positive individu- 
als, nephrology, and gastroenterology. All patients came 
from the Centre Hospitalier et Universitaire of Nancy, 
France, but six sera came from other hospitals of the 
Region Lorraine, France. 
Serologic Assays 
All tests were performed and interpreted according to 
the recommendations of the manufacturers. Two second- 
generation screening assays, HCV-ELATM (Abbott Labora- 
tories) and Monolisa anti-HCVTM (Sanofi, Diagnostic 
Pasteur, Marnes-la-Coquette, France) were run in parallel. 
The results were considered to be different if the posi- 
tivity levels were not identical (i.e., positivity at the upper 
limit for the first test and not for the second test). For con- 
venience, these sera were scored as +/+. If only one test 
was positive and the other negative, the sera were scored 
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Table 1. Relation between Interpretation of the Screening Test 











25 (62.5%) 33 
15 73 
34 (85%) 38 
6 68 
as +/-. Moreover, many results of this series also were 
inconclusive according to the manufacturer’s assay cri- 
teria, meaning that the absorbance value was in the gray 
area for either one or both tests. 
MATRIX-HCV2TM results were considered to be pos- 
itive if serum reacted with at least one antigen. For each 
antigen, a sample:cutoff ratio is given by the apparatus. 
Values over 1 were considered to be positive. For NS4, 
two different peptides were used, one cloned in 
Escherichia coli, the other in yeast. For retaining a posi- 
tive result with NS4, serum must react with these two 
antigens. Another supplemental assay, the HCV-EIATM sup- 
plemental assay, was run in parallel. Because its results 
did not give additional information compared to screen- 
ing tests, data have not been shown. 
Polymerase Chain Reaction 
after Reverse Transcription 
Hepatitis C virus RNA was detected by nested PCR 
according to the method of La&i et al, using external 
primers 1CH and ZCH, and internal ones 4TS and 4CH.3 
Briefly, after careful phenol chloroform and chloroform 
extraction, cDNA was synthesized using murine moloney 
leukemia virus RNA-dependent DNA polymerase (Life 
Technologies Ltd., Paisley, UK) and the antisense primer 
1 CH. Complementary DNA amplification was carried out 
in a thermocycler at temperatures of 95°C for DNA denat- 
uration, 42°C for annealing, and 72°C for DNA synthesis 
using Thermus aquaticus polymerase (Life Technologies 
Ltd.) The first round consisted of 35 cycles and the sec- 
ond, 25. Polymerase chain reaction products were ana- 
lyzed on a 2% agarose gel stained with ethidium bromide, 
using a molecular size marker for identifying the expected 
187 bp product. All PCR were run in duplicate. Sensitiv- 
ity of RT-PCR was estimated using the reference sera of 
the HCV RNA Quantification PanelTM (Boston Biomedica 
Inc., Boston, MA, USA). The detection threshold was deter- 
mined in triplicate and was 1000 to 5000 HCV RNA 
copies per milliliter of serum. 
Analysis of Results 
For each test specificity (Sp), sensitivity (Se), positive pre- 
dictive value (PPV), and negative predictive value (NPV) 
were calculated using results of RT-PCR as the reference. 
RESULTS 
Screening Tests 
For the screening tests, inconclusive results were pooled 
with the negative ones. Thus, only true-positive results 
were considered. A presence of RNA in sera correlated 
well with positivity of the screening tests (62.5% with 
HCV-EIATM and 85% with Monolisa anti-HCVT”) (Table 1). 
Two sera had given discrepant results on repeated testing 
(2 negative and 2 positive results), probably owing to an 
RNA concentration close to the detection threshold, and 
were considered to be true-positive (data not shown). 
Performance of Monolisa anti-HCVTM (PPV = 85%, 
NPV = 64%) was better than that of HCV-EIATM (PPV = 
63%, NPV = 69%), but the specificity of the two tests was 
low (92% and 83%, respectively). 
MATRIX-HCVZTM Assay 
The MATRIX-HCV2TM test had good specificity (97%) and 
positive predictive value (98%) despite a poor negative 
predictive value (27%). Of 40 sera, 39 (97%) that were 
RT-PCR-positive reacted with at least one antigen (Table 
2). The only false-negative corresponded to a borderline 
result with both NS4 antigens. Also the RT-PCR positiv- 
ity rate could not be related with an antigen type in the 
supplemental test: no difference was shown when the 
sera reacted with the C, NS3, or NS4 antigen (see Table 
2). Whether one or two peptides gave positive results 
did not make any difference in the rate of RT-PCR posi- 
tivity. The three sera that reacted with all three peptides 
were HCV-RNA-positive (100%). 
Table 2. Relation between Reactivity to Peptides of the MATRIX-HCV2TM Tesi and Results of Gene Amplification 
Positivity of MATRIX-HCV2TM 
0 Peptide 1 Peptide 2 Peptides 3 Peptides 
C NS3 NS4 C+NS3 C+NS4 NS3tNS4 C+NS3tNS4 
Number of sera (n = 146) 
RT-PCR positivity (n = 40) (28%) 1 q3, 3 go, 6 7:O) 
3 
2 (67) 3 (1300) 
*Corresponding to a borderline result with NS4 antigen. 
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Table 3. Correspondence between Interpretation of Serologic Test 
Results and Presence of RNA of Hepatitis C Virus in Serum 
Screening Test MATRIX-HCVZTM* RT-PCR+ 
+/+: 50 +: 49 (98%) +: 24 (48%) 
i-k : 30 +: 27 (90%) +: 11 (37%) 
Inconclusive: 66 +: 39 (59%) +: 5 (7%) 
Total: 146 +: 115 (79%) +: 40 (35%) 
In parentheses *the ratio of positive results in MATRIX-HCVTM test by the 
number of screening tests: +the ratio of positive results in RT-PCR by the 
number of positive in MATRIX-HCV2TM. 
For comparison, 21 sera were tested that gave strong 
positive results with the two screening tests (data not 
shown). MATRIX-HCVZTM gave positive results with three 
antigens for 14 sera (RT-PCR was positive 13 times, 93%) 
and with two antigens for seven sera (RTPCR was posi- 
tive 4 times, 57%). 
Sequence of Events 
As shown in Table 3, when the screening tests gave oppo- 
site results, 90% of sera reacted in MATRIX-HCV2TM and 
37% were HCV RNA-positive. These percentages drop 
respectively to 59% and 7% when the results of both 
screening tests were inconclusive. The rate of confirma- 
tion of an active virus replication as defined by RT-PCR 
positivity decreased along with a decrease of the posi- 
tivity in the supplemental test. 
DISCUSSION 
For the diagnosis of HCV infections at the time of this 
study, it was mandatory in France to run, in parallel, two 
screening tests that should be prepared using different 
antigens. Since October 12, 1997, (D&et du 31 Juillet 
1997, Journal Officiel du 12 Aozit 1997) a serologic test 
is required on the first serum and a second test is per- 
formed only if the first is positive or inconclusive. Despite 
a better specificity of serologic tests, false-positive results 
still are observed, thus interpretation of serology remains 
difficult. Inconclusive results require additional investiga- 
tions. Supplemental tests are supposed to help in the inter- 
pretation of serology, but this study shows their poor 
value, because they are poorly predictive of an active infec- 
tion. When 59% of inconclusive sera were positive with 
MATRKX-HCV2TM, only 7% corresponded to an active infec- 
tion as confirmed by RTPCR positivity (see Table 3). Thus 
the selection bias of the sera was responsible for the high 
positivity of the supplemental test. This would not be 
found if the sera have been randomly selected. 
A good concordance between RTPCR and RIBA 2.OTM 
(Recombinant ImmunoBlot Assay, Ortho DiagnosticsTM, 
Raritan, NJ, USA) has been reported in sera from blood 
donors.6z7 Positivity of RlBA 3.0TM corresponded to viremia 
in 39 high-risk patients (88%). Nonetheless, four of six 
indeterminate RIBA 3.0TM results corresponded to the 
presence of HCV RNA in sera.’ The increase in sensitivity 
and specificity of RIBA 3.0TM compared to RIBA 2.OTM 
does not seem related to the presence of NS5 but rather 
to an increased reactivity to NS3.9-12 Thus, the absence of 
NS5 in the MATRlXHCV2TM test may not be detrimental 
to its diagnostic value. In the present study, MATRIX- 
HCV2TM gave clear results for all tested sera, and only one 
diagnosis of HCV would have been missed with this test. 
The selection criteria of the 146 sera likely was responsi- 
ble for the high rate of reactivity with one to three pep- 
tides of HCV RNA-negative sera. In contrast, the 21 sera 
with strong reactivity with screening tests also were reac- 
tive with two or three antigens of the supplemental test. 
For these sera, the rate of RT-PCR positivity (81%) was in 
the range of previous data obtained with sera reacting with 
four or five peptides in a RIBA 3.0TM assay..‘* It is likely 
that results of the present study would have been closer 
to those found by Dow et al,12 if the patients had been 
selected without any a priori. 
Three major causes may explain discrepancies 
between RT-PCR and MATlUX-HCV2TM results: (1) past 
infection, (2) nonspecific reactivity, and (3) RNA serum 
level below the detection threshold. In the present series, 
the two first causes might be retained for explaining the 
high false-positive rate. In this study, RT-PCR showed good 
sensitivity, given that its detection threshold of internal 
control was close to the one given by BBI Laboratories, 
whether the extraction was done from plasma or serum 
(1000 RNA copies/ml serum). 
CONCLUSIONS 
Serology results must be considered with great caution; 
a positive result does not always indicate an active infec- 
tion. Furthermore, inconclusive results may correspond to 
an active infection in a limited number of cases. Because 
a precise diagnosis of hepatitis C is necessary in infected 
patients for an interferon and antiviral therapy to be pro- 
posed, RNA detection in serum is the only valuable test 
for this purpose. It should be considered to be the best 
diagnostic test, provided the sensitivity of the technique 
has been carefully evaluated. A negative result in patients 
with positive serology should be confirmed by another 
test in 3 weeks. Gene amplification should replace sup- 
plementary assay tests for a reliable direct diagnosis of 
active HCV infection to be made.3 
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